BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34637782)

  • 1. Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study.
    Valtcheva N; Nguyen-Sträuli BD; Wagner U; Freiberger SN; Varga Z; Britschgi C; Dedes KJ; Rechsteiner MP
    Exp Mol Pathol; 2021 Dec; 123():104705. PubMed ID: 34637782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    Stok C; Kok YP; van den Tempel N; van Vugt MATM
    Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting replication gaps for cancer therapy.
    Cong K; Cantor SB
    Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer.
    Sharifah NA; Nurismah MI; Lee HC; Aisyah AN; Clarence-Ko CH; Naqiyah I; Rohaizak M; Fuad I; A Jamal AR; Zarina AL; Nor Aina E; Normayah K; Nor Hisham A
    Cancer Epidemiol; 2010 Aug; 34(4):442-7. PubMed ID: 20451485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
    Rudnicka H; Debniak T; Cybulski C; Huzarski T; Gronwald J; Lubinski J; Gorski B
    Mol Biol Rep; 2013 Dec; 40(12):6619-23. PubMed ID: 24065545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and distribution of BRCA1/BRCA2 large genomic rearrangements in Turkish population with breast cancer.
    Akin Duman T; Ozturk FN
    J Hum Genet; 2023 Jul; 68(7):485-490. PubMed ID: 36864289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
    Löser H; Heydt C; Büttner R; Markiefka B
    Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex Characterization of Germline Large Genomic Rearrangements of the
    Bozsik A; Pócza T; Papp J; Vaszkó T; Butz H; Patócs A; Oláh E
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing.
    Han E; Yoo J; Chae H; Lee S; Kim DH; Kim KJ; Kim Y; Kim M
    Clin Chim Acta; 2020 Jun; 505():49-54. PubMed ID: 32092317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
    Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
    Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.